# EDGAR Filing Document

**Accession Number:** 0001140859
**File Stem:** 0001104659-23-000085
**Filing Date:** 2023-1
**Character Count:** 6804
**Document Hash:** 114e1a744d415560380265409ca8ec33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-000085.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001104659-23-000085

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230101

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMERISOURCEBERGEN CORP
- **CENTRAL INDEX KEY:** 0001140859
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **IRS NUMBER:** 233079390
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16671
- **FILM NUMBER:** 23500197

**BUSINESS ADDRESS:**
- **STREET 1:** 1 WEST FIRST AVENUE
- **CITY:** CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 6107277000

**MAIL ADDRESS:**
- **STREET 1:** 1 WEST FIRST AVENUE
- **CITY:** CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

?xml version="1.0" encoding="utf-8"?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 1, 2023

AmerisourceBergen Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 1-16671

---

| | |
|:---|:---|
| Delaware | 23-3079390 |
| (State or other jurisdiction of  | <br> (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
| 1 West First Avenue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conshohocken&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PA | <br> 19428-1800 |
| (Address of principal executive offices)  | (Zip Code)  |

---

(610) 727-7000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Name of exchange on which registered |
| &nbsp;&nbsp;Common stock &nbsp;&nbsp;ABC | &nbsp;&nbsp;New York Stock Exchange &nbsp;&nbsp;&nbsp;&nbsp; (NYSE) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp; ◻

Item 8.01 Other Events.

Effective January 1, 2023, AmerisourceBergen Corporation (the "Company") completed the previously announced acquisition of PharmaLex Holding GmbH. A copy of the Company's press release announcing the closing is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit Number | Description of Exhibit |
| [99.1](tm2233673d1_ex99-1.htm) | [News Release of AmerisourceBergen Corporation, dated January 3, 2023.](tm2233673d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document. |

---

<u>SIGNATURES</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | AMERISOURCEBERGEN CORPORATION | AMERISOURCEBERGEN CORPORATION |
| Date: | January 3, 2023 | By: | /s/ James F. Cleary |
|  |  | Name: | James F. Cleary |
|  |  | Title: | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
|  | **PRESS RELEASE** |
| ![](tm2233673d1_ex99-1img001.jpg) |  |
| ![](tm2233673d1_ex99-1img001.jpg) |  |
| ![](tm2233673d1_ex99-1img001.jpg) |  |
|  | AmerisourceBergen Corporation |
|  | 1 West First Avenue |
|  | Conshohocken, PA 19428 |

---

**AmerisourceBergen COMPLETES ACQUISITION OF PHARMALEX**

*Acquisition advances role as a partner of choice for biopharmaceutical companies by enhancing global portfolio of specialty services*

**CONSHOHOCKEN, PA, January 3, 2023** — AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.

The acquisition of PharmaLex enhances AmerisourceBergen's growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex's regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen's role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey.

**<u>About AmerisourceBergen</u>**

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

---

| | |
|:---|:---|
| **Contacts:** | **Investors:** |
|  | **Bennett S. Murphy** |
|  | **610-727-3693** |
|  | **bmurphy@amerisourcebergen.com** |
|  | **Media:** |
|  | **Lauren Esposito** |
|  | **215-460-6981** |
|  | **lesposito@amerisourcebergen.com** |

---